Results 211 to 220 of about 103,862 (301)

Repression of EGFR by new biguanide 4C potentiated ovarian cancer to PARP inhibitors through down-regulation of BRCA2 and Rad51. [PDF]

Cell Death Dis
Xiao D, Yao J, Yang X, Xie Y, Zhou X, Li D, Peng M, Wang W, Zou H, Yang X.   +9 more
europepmc   +1 more source

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging. [PDF]

EJNMMI Radiopharm Chem
Destro G, Rizzo R, Rua C, Azimi RR, Morbelli S.   +4 more
europepmc   +1 more source

Beyond Glucose: A Brain Energy Bottleneck Hypothesis for Multi‐Energy Substrates in Hypoglycaemia Rescue

Diabetes, Obesity and Metabolism, EarlyView.
D. Russell‐Jones, M. Laffan, J. Mader
wiley   +1 more source

Hyperthermia‐induced cytotoxicity and modulation of PD‐L1 and MHC‐I expression in human non‐small cell lung cancer cell lines

Experimental Physiology, EarlyView.
Abstract Hyperthermia has recently been applied to treat human non‐small cell lung cancer (NSCLC). However, the mechanisms underlying cytotoxic sensitivity of NSCLC cells to hyperthermia are not fully understood. In this study, five NSCLC cell lines with different epidermal growth factor receptor (EGFR), Kirsten rat sarcoma and tumor protein p53 ...
Yun‐Chieh Tu, Wei‐Chen Yeh, Yi‐Wei Fang, Ko‐Hsuan Lo, Lei‐Ni Liang, Xu‐Chen Liu, Chia‐Chi Tsai, Chih‐Cheng Cheng, Meng‐Chieh Lin, Hsin‐Hsien Yu, Bor‐Chyuan Su   +10 more
wiley   +1 more source

Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer. [PDF]

Target Oncol
Nishimyo K, Ishikawa KB, Aoki D, Fushimi K, Yamazaki T.   +4 more
europepmc   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, Volume 86, Issue 6, Page 727-731, May 2026.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source

Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair. [PDF]

J Exp Clin Cancer Res
Ni X, Li M, Qiu W, Han J, Yu M, Zhang S, Zheng B, He J, Liu H.   +8 more
europepmc   +1 more source

Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 5, May 2026.
Hetrombopag targeted PNPO to inhibit multiple myeloma. ABSTRACT Multiple myeloma (MM) is a malignancy of plasma cells whose excessive immunoglobulin production elevates reactive oxygen species (ROS), promoting pathogenesis. Active compounds from Traditional Chinese Medicine, such as celastrol, can exert antitumour effects by further increasing ROS ...
Tianyi Yu, Cheng Wang, Jingru Xie, Yongxin Wei, Hongwei Cui, Huaxia Zhang, Fan Zhou, Zhendong Deng, Ye Yang, Chunyan Gu   +9 more
wiley   +1 more source

Therapeutic advances and application of PARP inhibitors in breast cancer. [PDF]

Transl Oncol
Zhou T, Zhang J.
europepmc   +1 more source

Homoisoflavanone Delays Colorectal Cancer Progression via DNA Damage‐Induced Mitochondrial Apoptosis and Parthanatos‐Like Cell Death

Advanced Science, Volume 13, Issue 19, 2 April 2026.
Homoisoflavanone (HIF), a bioactive compound isolated from Polygonatum kingianum, selectively suppresses colorectal cancer progression by inducing DNA damage‐mediated mitochondrial apoptosis and parthanatos‐like cell death. HIF triggers mitochondrial dysfunction, including depolarized membrane potential, elevated ROS, and ATP depletion, while impairing
Hongjie Fan, Huzi Zhao, Pei Zhang, Pengfei Yu, Yunfei Ji, Gang Chen, Hongli Jin, Yanfang Liu, Jin Liu, Zhe‐Sheng Chen, Aiping Lyu, Xinmiao Liang, Yang Chen   +12 more
wiley   +1 more source